Affiliations

NYBA

Australia Biotech

BioMelbourne

Lab To Wall Street

Industry News

New Pharmaxis Board Appointment

24 June 2008 - Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors.

Mr Delaat has 35 years experience in the global pharmaceutical industry, most recently as the managing director of the Australian subsidiary of Merck & Co., a position he held from 1997 until his recent retirement.

During his career Mr Delaat has held executive positions in both Europe and Australia for Merck and AstraZeneca. Mr Delaat is experienced in sales and marketing and has been responsible for international product launches and commercialisation of respiratory products.

Mr Delaat also serves the pharmaceutical industry in important representative roles. He is chairman of the Australian pharmaceutical industry's peak body, Medicines Australia, and is chairman of the Pharmaceuticals Industry Council. "Will Delaat is one of Australia's pharmaceutical industry leaders" said Pharmaxis Chairman, Denis Hanley. "The Pharmaxis board will benefit from his invaluable skills and experience."

In accepting the board director position Mr Delaat said: "Pharmaxis holds enormous promise and I look forward to being part of its effort to bring innovative medicines to patients world-wide."

  May 28th, 2009:
Arana Therapeutics Board Changes

May 6th, 2009:
Circadian Scientific Advisory Board Chairman, Professor Kari Alitalo, Wins Prestigious Award for Biomedical Research

May 5th, 2009:
Living Cell Technologies Reports Insulin Independence in Two Patients Following Recent Implants of DIABECELL® in Diabetes Clinical Trial

November 3rd:
FDA Accepts Arana's Anti-inflammatory IND

September 4th:
Cytopia Commences Second Phase II Study in Brain Cancer

September 4th:
Pharmaxis Announces Second Pivotal Phase 3 Trial in Cystic Fibrosis Begins

August 6th:
Xenome Strengthens Board with Two New Appointments

August 6th:
Ciba Elects to Cease Industrial Product Evaluations

June 24th:
New Pharmaxis Board Appointment

April 29th:
Benitec secures further rights to HIV Therapeutic

more industry news >
 


osullivanpllc.com  

Disclaimer